INTRODUCTION
The advent of high-throughput techniques to study gene expression has led to the recognition that nearly 30-50% of the human genome is transcribed, and non-coding RNA represents a significant portion of this transcriptome (1, 2) . Perhaps the clearest example of functional non-coding RNA is microRNA (miRNA), which are dysregulated in cancer (reviewed in (3)). In oncogenesis, individual miRNAs have been found to act as either tumor suppressor genes or oncogenes, based on our work and that of others. A new addition to the repertoire of non-coding RNAs is long non-coding RNAs (lncRNAs) (4) . These RNAs are frequently found in intergenic regions, lack open reading frames, and have been detected in the transcriptome by high-throughput technologies (4, 5) . Although several classes of non-coding RNA species are being described, lncRNAs are unique in that there are epigenetic marks in their promoter regions (H3K4me3) and along transcribed regions (H3K36me3), identifying them as unique gene structures (6) . At the molecular level, lncRNAs regulate gene expression via transcription, repress microRNA activity by competitive binding, regulate splicing and activate transcription (7) (8) (9) (10) (11) (12) . At the cellular and organismal level, lncRNAs have been implicated in physiological processes, such as maintenance of embryonic stem cells and erythroid development during hematopoiesis (13) (14) (15) (16) (17) (18) . Extending their putative roles to pathologic conditions, prior studies have examined lncRNA expression in cell lines as well as in epithelial malignancies, finding dysregulated expression (19) .
Given that many hematopoietic malignancies result from mutations that cause dysregulation of gene expression, we reasoned that lncRNAs may play a role in the pathogenesis of these malignancies. Recent studies have demonstrated dysregulation of certain lncRNAs in hematopoietic malignancies, but the majority of these studies were relatively limited in their 4 scope (reviewed in (20) ). Amongst malignancies arising from hematopoietic precursors, B-acutelymphoblastic leukemia (B-ALL), a malignancy of precursor B-cells, has previously been shown to harbor mutations and translocations resulting in dysregulated gene expression (21) . Much progress has been made in understanding the molecular pathogenesis of B-ALL, including the role of chromosomal translocations. It is now well-recognized that commonly observed recurrent chromosomal abnormalities have distinct pathogenetic and prognostic implications (21, 22) .
However, to date, there has been no understanding of how lncRNAs may participate in the pathogenesis of this disease. Hence, we undertook a comprehensive study examining lncRNA expression in B-ALL, examining correlations with clinicopathologic parameters, and querying the functional consequences of lncRNA expression.
Here, we found that overall lncRNA expression corresponds with specific cytogenetic abnormalities in B-ALL and that a subset of lncRNAs could correctly predict the cytogenetic subtype of B-ALL amongst the three most common abnormalities. We termed these B-ALL associated long RNAs (BALRs). The four most differentially regulated lncRNAs were mapped to their chromosomal locations and transcripts originating from these genomic loci were sequenced. Interestingly, high expression of one lncRNA, BALR-2, was correlated with a poor patient response to prednisone and worse overall survival. Knockdown of BALR-2 caused an increase in apoptosis of B-ALL cell lines alone and in combination with prednisolone.
Interestingly, BALR-2 was repressed when human B-ALL cell lines were treated with prednisolone. Gene expression analyses of cells with knockdown of BALR-2 revealed activation of several genes involved in the response of B-cells to glucocorticoid receptor engagement.
Lastly, the expression of BALR-2 in B-ALL cell lines with low basal expression of this lncRNA led to resistance to prednisolone treatment and concordant changes in gene expression. Together 5 with our observation that BALR-2 is repressed by prednisolone treatment, our findings indicate a novel role for a non-coding RNA as a modulator of a treatment response. These data represent some of the first insights into long non-coding RNA expression in B-ALL and reveal that they play a role in pathogenesis, disease severity, and measurement/alteration of their levels may be useful in prognosis and/or treatment of this disease, respectively.
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MATERIALS AND METHODS
Patients and samples
The patient cohort consisted of 160 children consecutively admitted to the Pediatric Oncologic Department at the University of Padua, Italy, from 2000 to 2008 with the diagnosis of B-ALL.
Following analysis for RNA quality, we had a total of 44 patients for the microarray studies (cytogenetic information only) and 93 patients for RT-qPCR studies (comprehensive clinicopathologic information; See Supp Methods and Table 1 Data analysis was implemented in the R statistics package (24). The data from two microarray experiments (20 in the initial set and 24 in the validation set) were analyzed independently but following the same protocol. The Agilent feature extraction raw data files were loaded into the R environment and analyzed using the R library of Linear Models for Microarray Data (LIMMA) (25). The raw data were preprocessed for background correction and normalized between arrays using the quantile method, summarized by taking the average of replicates for each gene, and subsequently log 2 -transformed. Additional microarray data was generated from 4 different cultures of RS4;11 cells with or prednisolone treatment and with a siRNA against BALR-2 (or control vector). Samples were hybridized at the UCLA microarray core facility using Affymetrix HG-U133_Plus_2 microarray. Raw hybridization intensities were summarized and normalized using the RMA method (26) as implemented in Matlab (The Mathworks Inc.). Differential expression analysis was performed as previously described (27). Functional annotation of differentially expressed genes was retrieved from www.ingenuity.com. All data from the microarray studies have been deposited in the Gene Expression Omnibus (GEO) resource (GEO Series ID GSE65647).
Clinicopathologic data analysis. All data analysis was completed using SPSS software.
Clinicopathologic parameters (available for 93 patients) were correlated with the continuous qPCR data obtained for each of the lncRNAs using a Pearson's Chi-square, and two-tailed Ttests (for dichotomous variables). Next, Kaplan Meier analyses were performed using dichotomized variables as described in supplemental methods. 
Vectors
RT-qPCR and Western Blot
RNA collected from human samples was reverse transcribed using iScript reagent (Quanta Biosciences), RNA from cell lines was reverse transcribed using qScript (Quanta Biosciences).
Real Time quantitative PCR was performed with the StepOnePlus Real-Time PCR System (Applied Biosystems) using PerfeCTa SYBR Green FastMix reagent (Quanta Biosciences).
Primer sequences used are listed in Supp 
RESULTS
LncRNA expression segregates three common cytogenetic subtypes of B-ALL and can predict the cytogenetic subtype.
LncRNAs have been ascribed functions in both cancer causation and development of the hematopoietic system. Here, we undertook a microarray study to define patterns of lncRNA expression in different subsets of B-ALL using the Agilent SurePrintG3 Human GE 8x60K platform (4,7,31) (see Supp Fig 1 for experimental pipeline) . In our initial sample set, we hybridized 20 cases of B-ALL with three different common translocations. Following correction for multiple hypothesis testing, we performed unsupervised hierarchical clustering with significantly differentially expressed protein-coding genes (p-adj0.01), finding that the three cytogenetic subtypes separated into three subsets ( Fig 1A) . Interestingly, when we focused exclusively on lncRNAs (p-adj0.01), lncRNAs were differentially expressed across the 3 different cytogenetic subtypes, although MLL-translocated cases appeared to have the most distinctive lncRNA expression pattern (Fig 1B) . Interestingly, lncRNA expression seemed to be highly predictive of the cytogenetic abnormality in B-ALL. Using nearest shrunken centroid analysis, we determined that lncRNA expression is at least equivalent to protein coding gene expression at differentiating these three common cytogenetic abnormalities in an independent set of 24 cases of B-ALL (Supp Fig 2) . For instance, one case of ALL became misclassified when 113 protein-coding genes were used to classify the samples, whereas one could use 27 lncRNAs before the same case was misclassified (Supp putative oncogenic and tumor suppressor lncRNAs. These were designated as B-ALL associated long RNAs (BALRs), unless they had already been assigned LINC designations. Four lncRNAs were subsequently selected based on higher expression in leukemic versus normal B-cell precursors in the microarray, and the fact that these lncRNAs were located in well-annotated loci those that showed multiple ESTs or mRNA transcripts and were conserved in human and mouse genomes (Supp Fig 1) . These lncRNAs were BALR-1, BALR-2, BALR-6 and LINC00958
which were also the most differentially expressed in the different cytogenetic subtypes (Fig 1C-F ). Hence, lncRNAs are differentially regulated in B-ALL with specific translocations.
LncRNA expression is correlated with clinicopathologic parameters in a large set of B-ALL cases.
RT-qPCR was used to confirm the expression pattern of four individual lncRNAs in a subset of cases from the microarray cohort as well as in an independent set of B-ALL samples (Fig 2A-D) . qPCR primer sets with the most consistent behavior across technical replicates and serial dilutions were chosen (Supp Table 4 , qPCR primers). LncRNA expression was most consistently different in the subset of cases with MLL translocations, which is associated with a bad prognosis. For all four lncRNAs, we confirmed that MLL-translocated cases showed significantly different expression levels, compared with cases showing TEL-AML1, E2A-PBX1, or BCR-ABL translocations. Additionally, BALR-2 and BALR-6 expression was significantly upregulated in all subsets of patient samples when compared to normal CD19 + cells (Fig 2B-C) .
To examine the possibility that lncRNA expression is predictive of patient outcomes, we performed statistical analyses on available clinicopathologic parameters associated with these cases. Interestingly, BALR-2 expression was significantly higher in B-ALL patients that were unresponsive to prednisone as opposed to those who had a response to prednisone (Fig 2E, T- test, two-tailed p=0.0003). We dichotomized BALR-2 expression using a cut point based on cluster analysis (Supp Fig 3B) , and found that high BALR-2 expression was associated with inferior overall survival ( Fig 2F ; Kaplan Meier survival analysis; log-Rank test, p=0.005,).
Although BALR-2 expression did correlate with translocations, it should be noted that four of the poor-prognosis cases that had high BALR-2 expression did not contain a detectable translocation. When we attempted multivariate logistic regression, BALR-2 was not established as an independent prognostic variable (Supp Table 3 ). This may be due to insufficient numbers of cases with high BALR-2 expression in our cohort, and requires further study.
BALR-2 is a nucleocytoplasmic lncRNA whose expression is regulated by glucocorticoid treatment.
Given the interesting clinicopathologic findings with BALR-2, we began to study whether the expression of lncRNAs was regulated during treatment of B-ALL cells with chemotherapeutic agents. Interestingly, while the expression of these lncRNAs showed some variation with treatment, only BALR-2 was specifically regulated by glucocorticoid treatment (Fig 3A-D) . Specifically, BALR-2 was downregulated in two different B-ALL cell lines, RS4;11 and NALM6, following treatment with either prednisolone or dexamethasone, but not with doxorubicin ( Fig 3B) . This finding is in line with the idea that prednisolone treatment downregulates BALR-2, but in B-ALL with constitutively high BALR-2, the cells become resistant. Next, we characterized the subcellular localization of these four lncRNAs, finding that in contrast to the other three lncRNAs, BALR-2 expression was on the same order of magnitude in nuclear and cytoplasmic fractions; and was in fact higher in the cytoplasm in one set of experiments ( Fig 3E-H) . This was confirmed in multiple B-ALL cell lines, including RS4;11,
13
REH and 697, which show differing levels of expression of BALR-2 ( Fig 3F) . As expected GAPDH mRNA is primarily localized to the cytoplasm ( Fig 3I) and the nuclear RNA CELF4 is primarily in the nuclear fraction (Fig 3J) . Hence, BALR-2 expression appears to be regulated by glucocorticoid treatment and significant amounts of BALR-2 are found in the cytoplasm, making this lncRNA amenable to siRNA mediated knockdown.
Knockdown of BALR-2 results in growth inhibition and increased apoptosis.
Given the correlation of BALR-2 with overall survival, we first characterized its chromosomal location, 7q21.2. The area surrounding BALR-2 is conserved in mammals and mRNA NR_110088 is localized to this region ( Fig 4A) . Similar gene diagrams are provided for the other three lncRNAs in Supp Fig 4a-c. To map the transcript, we carried out 5'RACE and 3'RACE using mRNA extracted from B-ALL cell line RS4;11. We confirmed the annotated mRNA and an alternate splice form with a previously unannotated exon (Supp Fig 4D) . 3' RACE confirmed the transcript as being approximately 500 base pairs in length (Supp Table 4 ).
This transcript lacked an open reading frame and translation initiation site, and was predicted to be non-coding (32). Vertebrate PhastCons analysis demonstrated significant conservation within the terminal exon in 91 vertebrate species, suggesting a functional transcript (Fig 4B) . Moreover, analysis of H3K4m3 and H3K36m3 revealed that signals along the promoter and gene body are consistent with a transcriptional element (Fig 4C) (33). To define a functional role for this transcript in B-ALL, siRNAs against BALR-2 were cloned into a modified lentiviral vector using miRNA formatted flanking and loop sequences (28,30). These lentiviral constructs were used to transduce the RS4;11 cell line ( Fig 4D) . RS4;11 cells stably expressing siRNA against BALR-2
showed significantly decreased proliferation, measured by MTS (Fig 4E) . Decreased cell 14 viability and increased apoptosis was observed both at baseline (data not shown) and after treatment with prednisolone ( Fig 4F-G) (34,35) . In line with cell proliferation data, RS4;11 cells treated with siRNAs1-3, revealed an increase in G0-G1-phase, as well as a decrease in S-and G2-M phase, as measured by propidium iodide staining. A significant increase in apoptotic cells (cells in Sub-G0 phase) was observed in cells treated with siRNAs2-3 ( Fig 4H) .
BALR-2 regulates apoptosis by modulating the glucocorticoid receptor signaling pathway.
To examine the mechanism by which BALR-2 affects proliferation and apoptosis in B-ALL cell lines, we examined gene expression in RS4;11 cell lines stably transduced with siRNA2 (which showed the greatest degree of knockdown against BALR-2), with and without prednisolone treatment. Hierarchical clustering analysis identified clusters ( Figure 5A -B) of genes that were upregulated in the siRNA group, both with and without prednisolone treatment.
Several of these clusters consist of genes involved in the glucocorticoid receptor signaling pathway, confirmed by functional annotation results (2-4 fold increases in FOS, HSPA6, SGK1, IL8, JUN, SERPINE1, CDKN1A and ICAM1 in siRNA group, both with and without prednisone treatment; Fig 5B and 5C ). We confirmed knockdown of BALR-2 and upregulation of FOS, JUN, SGK1 and SERPINE1 by RT-qPCR (Supp Fig 5 A-E) . When we tried to validate the findings with multiple siRNAs, expression of JUN showed the most consistent changes ( Fig   5D) . We also observed upregulation of the pro-apoptotic protein BIM, which is a downstream target of JUN and an important mediator of glucocorticoid-induced apoptosis of lymphocytic cells (36) (Fig 5E) . Hence, BALR2 knockdown mirrored the effects of prednisolone treatment, which also resulted in induction of apoptosis and increased expression of JUN and BIM (Fig 5F-H ).
To confirm our findings, we tested additional cell lines that show high-level expression of BALR-2, including Nalm-6, Reh, and MV4;11. The glucocorticoid signaling pathway is operant in Nalm-6 cells, despite this cell line not carrying an MLL translocation (Supp Fig 5F-H) .
Consistent with our data in RS4;11 cells, knockdown of BALR-2 in Nalm-6 cells resulted in decreased cell proliferation, increased apoptosis, and increased expression of FOS (siRNA1 and 2), JUN (siRNA1), and BIM (siRNA1 and 2) (Supp Fig 6 A-D (Supp Fig 6K-M) . Overall, these findings demonstrated parallel effects of prednisolone treatment and BALR-2 knockdown in multiple cell lines, suggesting that BALR-2 is an important regulator of this pathway.
The function of BALR-2 is conserved in human and mouse cells.
To assess functional conservation of BALR-2, we mapped and characterized murine Balr-2 to 5qA1, and the murine transcript demonstrates 90% homology to the human sequence (Fig 6A) . RACE was performed and two products were identified at this locus (Supp Fig 4E) .
We generated miRNA-formatted siRNAs (30) against the murine transcript and confirmed decreased expression in the murine pre-B cell line 70Z/3 (Fig 6B) . Similar to what we observed in human cell lines, Balr-2 knockdown led to an upregulation of Fos and Jun in all three of the cell lines with upregulation of Bim in two out of three cell lines by RT-qPCR (Fig 6C-E) . We further confirmed the upregulation of these proteins by western blot analysis, finding increased expression Fos, Jun and Bim with all three knockdown constructs (Fig 6F) . Prednisolone treatment in the murine cells led to downregulation of Balr-2 concomitant with increased apoptosis, and upregulation of Fos, Jun, and Bim (Fig 6G-K) , mirroring our observations in the human cells. Our data indicate that BALR-2 plays a key role in regulating the glucocorticoid receptor signaling pathway, thereby regulating the cellular response to prednisolone treatment (A putative schematic mechanism is presented in Supp Fig 7) .
Enforced expression of BALR-2 promotes cell growth and inhibits apoptosis.
Given that normal and malignant B-lymphoid cells show markedly differential expression of BALR-2, we wanted to investigate the effects of gain-of-function of BALR-2. We designed and validated a MSCV-based two-promoter vector to constitutively express BALR-2 in E2A-PBX translocated 697 cells, which show very low basal levels of BALR-2 ( Fig 7A) . In juxtaposition to knockdown, overexpression of BALR-2 resulted in increased growth of the cells, as measured by MTS assay (Fig 7B) . Remarkably, overexpression of BALR-2 led to a partial rescue of prednisolone-induced apoptosis in 697 cells (Fig 7C) . Baseline levels of apoptosis were also somewhat lower with overexpression, but this finding was not statistically significant. Also in line with its anticipated function, the expression of FOS, JUN, and BIM was reduced (Fig 7D-F ). These findings suggest that BALR-2 plays a similar function in primary human B-ALL, leading to prednisone resistance and a poor prognosis. Next, we used the retroviral vector system to overexpress Balr-2 in murine 70Z/3 cells (Fig 7G) . This led to similar changes in gene expression as observed in 697 cells. Moreover, the expression changes of Fos, Jun, and Bim were the opposite of those seen with knockdown of Balr-2 ( Fig. 7H-J) . Hence, knockdown and overexpression of BALR-2 led to opposing phenotypes and gene expression changes in human and mouse cells, consistent with the role we propose here, and once again suggesting a conserved function for this lncRNA.
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DISCUSSION
In this report, we describe how long non-coding RNAs may play a role in B-ALL pathogenesis. We find that patterns of lncRNA expression are correlated with and can predict certain common chromosomal translocations in B-ALL. We found that expression of one lncRNA, BALR-2, correlated with overall survival and with response to prednisone. To characterize this functionally, we successfully knocked down BALR-2, finding increased apoptosis with chemotherapy. Most interestingly, we demonstrate a putative mechanism for BALR-2 in regulating cell survival in B-ALL-namely, that it is downregulated by glucocorticoid receptor engagement, and that its downregulation results in activation of the glucocorticoid receptor signaling pathway. These findings were conserved in human and murine B-ALLderived cells, and were achieved with multiple siRNA sequences targeting either the exonic mRNA sequence that we have defined here, or via targeting of exon-intron boundaries (37).
Our results present some of the first clinicopathologic correlations with lncRNA expression data in B-ALL, along with a recent publication that reports dysregulated lncRNA expression in B-ALL (38). Due to the limitations of the microarray platform, we may not have completely profiled all lncRNAs, and future efforts via high throughput RNA sequencing as well as alternate array platforms may yield additional relevant lncRNAs. Nonetheless, we found several correlations between the expression level of a few specific lncRNAs and clinicopathologic parameters. These studies validate the idea that lncRNAs are important players in biological processes and are tied to oncogenesis. Although BALR-2 expression segregated mainly with MLL-translocated cases in the curated data set, there were several cases of B-ALL without translocations that also showed high level expression of BALR-2. We suggest that the expression level of BALR-2 may represent another variable for prognostication in this disease.
Although high-risk cytogenetic abnormalities characterize the majority of patients who do not respond well to therapy, we suggest further study of BALR-2 expression, with a view towards prospectively identifying patients who will not respond well to standard therapeutic interventions. This is particularly relevant in the context of responsiveness to prednisone.
Although not addressed in this study, lncRNA expression in other types of leukemia may also represent a prognostic and therapeutically relevant variable, and warrants further study. Analysis of BALR-2 expression data and response to prednisone treatment shows that BALR-2 expression is significantly higher in B-ALL patients that are not responsive (NR) to prednisone compared to those who do respond to prednisone (R). Number of cases used in this analysis:
Responsive, n = 81; Non-Responsive, n = 8. RT-qPCR assays were normalized to ACTIN.
Comparisons made using a two-tailed T-test, p<0.05 (*); p<0.005 (**); p<0.0005 (***); p<0.0001 (****). (F) Kaplan Meier survival analysis for two patient groups shows that high BALR-2 expression is associated with poor overall survival (overall survival (OS) high = 62.5%
(n = 8), OS low = 91.5% (n = 82), log-Rank test, p=0.005). The two groups were dichotomized based on two step cluster analysis using SPSS software. Comparisons made using a two-tailed T-test, p<0.05 (*); p<0.005 (**); p<0.0005 (***). Overall, the effects of the siRNA are similar to those induced by prednisolone treatment.
Comparisons made using a two-tailed T-test, p<0.05 (*); p<0.005 (**); p<0.0005 (***). 
